Dr. Stavenhagen brings over 20 years of experience in leading drug discovery initiatives, with a focus on monoclonal antibodies targeting neuro diseases Jennifer Davis Ruff also named Vice President, Head of Investor Relations & Corporate Affairs with over 20 years of experience at leading public biopharmaceutical companies NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr.

TD Cowen initiated coverage of Dianthus Therapeutics with a rating of Buy

Oppenheimer initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $48.00

Robert W. Baird initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $58.00

Cantor Fitzgerald initiated coverage of Dianthus Therapeutics with a rating of Overweight

H.C. Wainwright initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $40.00

Stifel initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $44.00

Jefferies initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $22.00

Wedbush initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $23.00

Guggenheim initiated coverage of Dianthus Therapeutics with a rating of Buy and set a new price target of $45.00

Raymond James initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $24.00

SCHEDULE 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

10-Q - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

RW - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

424B5 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

424B3 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

EFFECT - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

EFFECT - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

S-3 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

SC 13G - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

SC 13D/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February: Guggenheim SMID Cap Biotech Conference – Fireside chat on February 6 at 9:00 a.m. ET in New York CityOppenheimer 35th Annual Healthcare Life Sciences Conference – Fireside chat on February 12 at 3:20 p.m. ET, taking place virtually Live webcasts of th

NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco. A live webcast of the Company's presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDiant

Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24 Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor Neuropathy (MMN) ongoing; top-line results anticipated in 2H'26 Approximately $343 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmu

NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024: Guggenheim Healthcare Innovation Conference on November 11 at 1:30 p.m. ET in Boston, MAJefferies Global Healthcare Conference on November 19 at 9:00 a.m. GMT in London7th Annual Evercore HealthCONx Conference on December 4 at 1

NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia. DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for p

NEW YORK and WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of September: Baird 2024 Global Healthcare Conference on September 11 at 2:00 p.m. ET in New York CityCantor 2024 Global Healthcare Conference on September 17 at 10:55 a.m. ET in New York CityStifel 2024 Virtual Immunology and Inflammation Sum

Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H'25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June; top-line results anticipated in 2H'26 Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to initiate 2H'24 Approximately $361 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the se

NEW YORK and WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN), taking place June 29-July 2, 2024 in Helsinki. DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for patients with generalized Myasthenia Gravis, Mult

Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) in 1Q'24 and planned initiation of a Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 2H'24 Recently disclosed head-to-head affinity and PD potency data reinforce DNTH103 is a highly potent, potential best-in-class active C1s inhibitor designed for self-administration in a low-volume, subcutaneous autoinjector once every two weeks NEW YORK and WALTHAM, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASD

NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Thursday, June 6, 2024 at 1:30 p.m. ET in New York. A live webcast of this presentation may be accessed under "News and Events" in the Investors section of the Dianthus Therapeutics website. About Dianthus TherapeuticsDianthus Therapeutics is a clinical-stage biotechnology comp